Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,915 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. Shanmugasundaram K, et al. Among authors: martin p. Eur J Haematol. 2021 Sep;107(3):301-310. doi: 10.1111/ejh.13649. Epub 2021 Jun 17. Eur J Haematol. 2021. PMID: 33973276 Free PMC article.
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. Ann Oncol. 2008 Jul;19(7):1327-1330. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17. Ann Oncol. 2008. PMID: 18349031 Free article.
Outcome of deferred initial therapy in mantle-cell lymphoma.
Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. J Clin Oncol. 2009 Mar 10;27(8):1209-13. doi: 10.1200/JCO.2008.19.6121. Epub 2009 Feb 2. J Clin Oncol. 2009. PMID: 19188674
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
Elstrom RL, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Elstrom RL, et al. Among authors: martin p. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):192-6. doi: 10.3816/CLML.2010.n.030. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20511164
Advancing through maintenance in mantle cell lymphoma.
Martin P, Leonard JP. Martin P, et al. Leuk Lymphoma. 2011 Sep;52(9):1617-8. doi: 10.3109/10428194.2011.586078. Epub 2011 Jun 23. Leuk Lymphoma. 2011. PMID: 21699376 No abstract available.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Leonard JP, et al. Among authors: martin p. Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1. Blood. 2012. PMID: 22383795 Free article. Clinical Trial.
7,915 results